
Opinion|Videos|January 10, 2025
Incorporating Emerging BTK Therapies Into the CLL Treatment Landscape
Panelists discuss how emerging data from ASH 2024 and recent NCCN guidelines supporting pirtobrutinib use in later-line CLL treatment are prompting oncologists to carefully evaluate factors like BTK resistance patterns and the potential role of novel BTK degraders when selecting therapy for relapsed/refractory patients.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- With the recent NCCN update recommending pirtobrutinib as a second line or later option, and in light of the BRUIN CLL-321 data presented at the 2024 American Society of Hematology annual meeting, what factors should oncologists consider when incorporating newer agents like pirtobrutinib into the treatment of relapsed/refractory chronic lymphocytic leukemia (CLL)?
- What is the significance of novel Bruton tyrosine kinase (BTK) degraders such as NX-5948, and how might they fill therapeutic gaps in BTK-resistant or intolerant relapsed/refractory CLL populations?
Advertisement
Related to this article

CRC diagnoses after endoscopic mucosal resection (EMR) were uncommon in a real-world cohort, though racial and ethnic differences remain unclear.

San Francisco experts say earlier IgA nephropathy and FSGS detection depends on primary care education and care coordinators.

The FDA has approved secukinumab for PMR after the REPLENISH trial showed doubled sustained remission and lower steroid use vs a steroid taper alone.

Earlier MASH fibrosis detection is more urgent now that treatments exist, and automating FIB-4 in EHRs could help primary care, says Rohit Loomba, MD.

In this Q&A, Jesús Corral Jaime, MD, discusses real-world CEMI-LUNG data on cemiplimab in advanced NSCLC presented at the ESMO 2026 Congress.

Neladalkib earned accelerated approval for previously treated ALK-positive NSCLC, with ORRs of 49% and 32%.
Advertisement
Advertisement

